Literature DB >> 9861017

Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.

S N Jones1, A R Hancock, H Vogel, L A Donehower, A Bradley.   

Abstract

The Mdm2 proto-oncogene is amplified to high copy numbers in human sarcomas and is overexpressed in a wide variety of other human cancers. Because Mdm2 protein forms a complex with the p53 tumor suppressor protein and down-regulates p53 function, the oncogenic potential of Mdm2 is presumed to be p53-dependent. To model these conditions in mice, we have used the entire Mdm2 gene, under transcriptional control of its native promoter region, as a transgene to create mice that overexpress Mdm2. The transgenic mice are predisposed to spontaneous tumor formation, and the incidence of sarcomas observed in the Mdm2-transgenic mice in the presence or absence of functional p53 demonstrates that, in addition to Mdm2-mediated inactivation of p53, there exists a p53-independent role for Mdm2 in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9861017      PMCID: PMC28091          DOI: 10.1073/pnas.95.26.15608

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin.

Authors:  T Watanabe; T Hotta; A Ichikawa; T Kinoshita; H Nagai; T Uchida; T Murate; H Saito
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

2.  mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein.

Authors:  J Chen; X Wu; J Lin; A J Levine
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

3.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.

Authors:  R Montes de Oca Luna; D S Wagner; G Lozano
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

4.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

5.  MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors.

Authors:  T Nakayama; J Toguchida; B Wadayama; H Kanoe; Y Kotoura; M S Sasaki
Journal:  Int J Cancer       Date:  1995-10-20       Impact factor: 7.396

6.  Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.

Authors:  C Cordon-Cardo; E Latres; M Drobnjak; M R Oliva; D Pollack; J M Woodruff; V Marechal; J Chen; M F Brennan; A J Levine
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

7.  Interaction between the retinoblastoma protein and the oncoprotein MDM2.

Authors:  Z X Xiao; J Chen; A J Levine; N Modjtahedi; J Xing; W R Sellers; D M Livingston
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

8.  Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein.

Authors:  K Martin; D Trouche; C Hagemeier; T S Sørensen; N B La Thangue; T Kouzarides
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

9.  Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2.

Authors:  A Forus; V A Flørenes; G M Maelandsmo; P S Meltzer; O Fodstad; O Myklebost
Journal:  Cell Growth Differ       Date:  1993-12

10.  Cell type-specific inhibition of p53-mediated apoptosis by mdm2.

Authors:  Y Haupt; Y Barak; M Oren
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

View more
  136 in total

1.  Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation.

Authors:  Gaëlle Legube; Laetitia K Linares; Claudie Lemercier; Martin Scheffner; Saadi Khochbin; Didier Trouche
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

2.  MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon.

Authors:  N Vlatkovic; S Guerrera; Y Li; S Linn; D S Haines; M T Boyd
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

3.  Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.

Authors:  Shunbin Xiong; Vinod Pant; Young-Ah Suh; Carolyn S Van Pelt; Yongxing Wang; Yasmine A Valentin-Vega; Sean M Post; Guillermina Lozano
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

4.  Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.

Authors:  Woon-Puay Koh; David Van Den Berg; Aizhen Jin; Renwei Wang; Jian-Min Yuan; Mimi C Yu
Journal:  Breast Cancer Res Treat       Date:  2011-07-21       Impact factor: 4.872

Review 5.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

Review 6.  MDM2 and mitochondrial function: One complex intersection.

Authors:  Camila Rubio-Patiño; Andrew Paul Trotta; Jerry Edward Chipuk
Journal:  Biochem Pharmacol       Date:  2018-11-01       Impact factor: 5.858

7.  SCFFBXO22 targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis.

Authors:  Jin Bai; Kenneth Wu; Meng-Han Cao; Yingying Yang; Yu Pan; Hui Liu; Yizhou He; Yoko Itahana; Lan Huang; Jun-Nian Zheng; Zhen-Qiang Pan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-28       Impact factor: 11.205

8.  Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.

Authors:  Aishwarya G Jacob; Dennis O'Brien; Ravi K Singh; Daniel F Comiskey; Robert M Littleton; Fuad Mohammad; Jordan T Gladman; Maria C Widmann; Selvi C Jeyaraj; Cheryl Bolinger; James R Anderson; Donald A Barkauskas; Kathleen Boris-Lawrie; Dawn S Chandler
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

9.  MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

Authors:  Maria Maguire; Paul C Nield; Timothy Devling; Rosalind E Jenkins; B Kevin Park; Radoslaw Polański; Nikolina Vlatković; Mark T Boyd
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 10.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.